Images
La Vanguardia, La Razón, Correo Farmacéutico, Health Canal, among other national and international media, have published an article about the research led by Antonio Zorzano, from IRB Barcelona, and Fernando Albericio, from the University of Barcelona. This study reveals activators of mitochondrial protein Mitofusin 2 that may be valuable in the treatment of type 2 diabetes.
Link to La Vanguardia
Link to Correo Farmacéutico
Link to Health Canal
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).
